Francis W. Hunter

1.0k total citations
19 papers, 696 citations indexed

About

Francis W. Hunter is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Francis W. Hunter has authored 19 papers receiving a total of 696 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in Francis W. Hunter's work include Cancer, Hypoxia, and Metabolism (11 papers), Epigenetics and DNA Methylation (5 papers) and DNA Repair Mechanisms (3 papers). Francis W. Hunter is often cited by papers focused on Cancer, Hypoxia, and Metabolism (11 papers), Epigenetics and DNA Methylation (5 papers) and DNA Repair Mechanisms (3 papers). Francis W. Hunter collaborates with scholars based in New Zealand, United States and Canada. Francis W. Hunter's co-authors include William R. Wilson, Bradly G. Wouters, Barbara Lipert, Stephen M. F. Jamieson, Martine Piccart, Christos Sotiriou, Géraldine Gebhart, Françoise Rothé, Jingli Wang and Michael P. Hay and has published in prestigious journals such as Cancer Research, Free Radical Biology and Medicine and British Journal of Cancer.

In The Last Decade

Francis W. Hunter

18 papers receiving 689 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francis W. Hunter New Zealand 12 295 279 263 143 124 19 696
Gustavo Lorente United States 9 471 1.6× 212 0.8× 354 1.3× 75 0.5× 86 0.7× 13 854
Lynsey A. Huxham Canada 13 276 0.9× 300 1.1× 147 0.6× 100 0.7× 134 1.1× 15 806
Misato Takigahira Japan 16 419 1.4× 316 1.1× 172 0.7× 33 0.2× 136 1.1× 22 845
Hitomi Sudo Japan 17 246 0.8× 235 0.8× 100 0.4× 289 2.0× 51 0.4× 56 766
Sherry A. Weppler Netherlands 10 504 1.7× 144 0.5× 307 1.2× 57 0.4× 52 0.4× 11 836
Ingrid J.G. Burvenich Australia 14 288 1.0× 236 0.8× 156 0.6× 231 1.6× 48 0.4× 49 669
Ina Kurth Germany 18 600 2.0× 544 1.9× 400 1.5× 86 0.6× 140 1.1× 38 1.2k
Igor Bado United States 13 331 1.1× 388 1.4× 184 0.7× 57 0.4× 63 0.5× 16 690
Alyssa Vito Canada 11 204 0.7× 210 0.8× 139 0.5× 103 0.7× 95 0.8× 18 555
Diana Spiegelberg Sweden 14 308 1.0× 279 1.0× 93 0.4× 120 0.8× 40 0.3× 31 555

Countries citing papers authored by Francis W. Hunter

Since Specialization
Citations

This map shows the geographic impact of Francis W. Hunter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francis W. Hunter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francis W. Hunter more than expected).

Fields of papers citing papers by Francis W. Hunter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francis W. Hunter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francis W. Hunter. The network helps show where Francis W. Hunter may publish in the future.

Co-authorship network of co-authors of Francis W. Hunter

This figure shows the co-authorship network connecting the top 25 collaborators of Francis W. Hunter. A scholar is included among the top collaborators of Francis W. Hunter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francis W. Hunter. Francis W. Hunter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Lipert, Barbara, Aziza Khan, Gitte Dam, et al.. (2025). CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance. Breast Cancer Research. 27(1). 48–48. 2 indexed citations
3.
Lee, Tet Woo, Dean C. Singleton, Moana Tercel, et al.. (2024). Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models. Molecular Oncology. 18(8). 1885–1903. 1 indexed citations
4.
Lee, Tet Woo, Francis W. Hunter, Peter Tsai, et al.. (2023). Clonal dynamics limits detection of selection in tumour xenograft CRISPR/Cas9 screens. Cancer Gene Therapy. 30(12). 1610–1623. 2 indexed citations
5.
Spiller, Krista J., Myrna A. Dominique, Hong Xu, et al.. (2021). Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery. Acta Neuropathologica Communications. 9(1). 34 indexed citations
6.
Lipert, Barbara, et al.. (2019). Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361. Biochemical Pharmacology. 169. 113641–113641. 23 indexed citations
7.
Lee, Tet Woo, et al.. (2019). Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia. International Journal of Radiation Biology. 95(12). 1597–1612. 37 indexed citations
8.
Hunter, Francis W., Barbara Lipert, Françoise Rothé, et al.. (2019). Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. British Journal of Cancer. 122(5). 603–612. 213 indexed citations
9.
Lipert, Barbara, Aziza Khan, Peter Tsai, et al.. (2019). Functional CRISPR knockout screens for modifiers of sensitivity to trastuzumab emtansine. Annals of Oncology. 30. iii22–iii22. 1 indexed citations
10.
Hunter, Francis W., Fanying Meng, Aziza Khan, et al.. (2019). Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide. Molecular Pharmacology. 95(6). 638–651. 14 indexed citations
11.
Lee, Tet Woo, Tao Wang, John M. Chaplin, et al.. (2019). Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models. Cells. 8(7). 717–717. 16 indexed citations
12.
Jaiswal, Jagdish K., Frederik B. Pruijn, Francis W. Hunter, et al.. (2018). Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects. Biochemical Pharmacology. 156. 265–280. 22 indexed citations
13.
Anderson, Robert F., Dan Li, & Francis W. Hunter. (2017). Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer. Free Radical Biology and Medicine. 113. 564–570. 8 indexed citations
14.
Hunter, Francis W., Bradly G. Wouters, & William R. Wilson. (2016). Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. British Journal of Cancer. 114(10). 1071–1077. 171 indexed citations
15.
Tran, Khanh Bao, et al.. (2016). 412P Effects of statins on melanoma. Annals of Oncology. 27. ix128–ix128. 1 indexed citations
16.
Hunter, Francis W., Richard J. Young, Zvi Shalev, et al.. (2015). Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. Cancer Research. 75(19). 4211–4223. 59 indexed citations
17.
Hunter, Francis W., et al.. (2014). Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 13(11). 2501–2514. 35 indexed citations
18.
Hunter, Francis W., Jagdish K. Jaiswal, Daniel Hurley, et al.. (2014). The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs. Biochemical Pharmacology. 89(2). 224–235. 22 indexed citations
19.
Hunter, Francis W., et al.. (2011). Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: Comparison with other hypoxia-activated prodrugs. Biochemical Pharmacology. 83(5). 574–585. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gustavo Lorente Breakdown of academic impact, for papers by Lynsey A. Huxham Breakdown of academic impact, for papers by Misato Takigahira Breakdown of academic impact, for papers by Hitomi Sudo Breakdown of academic impact, for papers by Sherry A. Weppler Breakdown of academic impact, for papers by Ingrid J.G. Burvenich Breakdown of academic impact, for papers by Ina Kurth Breakdown of academic impact, for papers by Igor Bado Breakdown of academic impact, for papers by Alyssa Vito Breakdown of academic impact, for papers by Diana Spiegelberg
Rankless by CCL
2026